nach oben

Wiener klinische Wochenschrift

Erschienen in:

01.07.2016 | original article

Effects of levodopa therapy on global left ventricular systolic function in patients with Parkinson disease

verfasst von: Zeki Yüksel Günaydın, M.D., Osman Bektaş, Ahmet Karagöz, Fahriye Feriha Özer

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 13-14/2016

Einloggen, um Zugang zu erhalten

Summary

Objectives

Since levodopa was identified as an efficient therapeutic option in Parkinson disease (PD), great success has been achieved in the course and treatment of the disease. However, L‑dopa-related side effects limit the therapeutic use in some patients. The aim of this study was to evaluate the effects of L‑dopa therapy on left ventricular global systolic function via speckle tracking method.

Methods

In this study, 55 patients with PD under L‑dopa/dopa decarboxylase inhibitor therapy were compared with 30 age- and sex-matched control subjects. Conventional transthoracic echocardiography was performed in the left lateral position by two experienced operators in accordance with generally accepted guidelines. Left ventricular systolic function was analyzed by speckle tracking method using global longitudinal strain (GLS) and global circumferential strain (GCS) imaging.

Results

Adequate echocardiographic imaging for the evaluation of global longitudinal strain and global circumferential strain could be achieved in 55 of the patients. LVEF (left ventricular ejection fraction), GLS and GCS values were found to be similar between the patients with PD under L‑dopa therapy and the control group (62 ± 3.5 % vs 61 ± 4 %, p < 0.05; −19.46 ± 2.3 vs −19.4 ± 3.2, p < 0.05; and −18.60 ± 3.5 vs −18.22 ± 3.2, p < 0.05 respectively.)

Conclusion

Levodopa therapy has no unfavorable effect on left ventricular systolic function in patients with PD.

Vorheriger Artikel Horizontal ECG in acute anterolateral myocardial infarction

Nächster Artikel MUW researcher of the month

LeWitt PA. Therapy with dopaminergic drugs in Parkinson’s disease. In: Koller WC, editor. Handbook of Parkinson’s disease. New York: Marcel Dekker; 1992. pp. 469–507.

Marsden CD. Parkinson’s disease. Lancet. 1990;335(8695): 948–52.CrossRefPubMed

Ahlskog JE. Parkinson’s disease: is the initial treatment established? Curr Neurol Neurosci Rep. 2003;3(4):289–95.CrossRefPubMed

Fahn S. A new look at levodopa based on the ELLDOPA study. J Neural Transm Suppl. 2006;70:419–26.CrossRefPubMed

Di Stefano A, Sozio P, Cerasa LS, Iannitelli A. L‑Dopa prodrugs: an overview of trends for improving Parkinson’s disease treatment. Curr Pharm Des. 2011;17(32):3482–93.CrossRefPubMed

Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson’s disease: pathogenetic and therapeutic studies. Ann Neurol. 1987;22(4):475–9.CrossRefPubMed

Tolosa E, Valldoriola F, Marti MJ. New and emerging strategies for improving levodopa treatment. Neurology. 1994;44(Supp 6):35–44.

Iodice V, Low DA, Vichayanrat E, Mathias CJ. Cardiovascular autonomic dysfunction in MSA and Parkinson’s disease: similarities and differences. J Neurol Sci. 2011;310(1–2):133–8.CrossRefPubMed

Fall PA, Saleh A, Fredrickson M, Olsson JE, Granerus AK. Survival time, mortality, and cause of death in elderly patients with Parkinson’s disease: a 9‑year follow-up. Mov Disord. 2003;18(11):1312–26.CrossRefPubMed

10.

Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort. Mov Disord. 2004;19(1):49–53.CrossRefPubMed

11.

Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. The unified Parkinson’s disease rating scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738–50.CrossRef

12.

Fahn S, Elton RL. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldsteijn M, Calne DB, editors. Recent developments in Parkinson’s disease. Florham Park: Macmillan Healthcare Information; 1987. pp. 153–63.

13.

Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427–42.CrossRefPubMed

14.

Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–63.CrossRefPubMed

15.

Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002;15(2):167–84.CrossRefPubMed

16.

Geyer H, Caracciolo G, Abe H, et al. Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications. J Am Soc Echocardiogr. 2010;23(4):351–69.CrossRefPubMed

17.

Kelton T, Mc CH, Scarfo K, Hecker JG. Neurologic diseases. In: Fleisher LA, editor. Anesthesia and uncommon diseases, 5th edn. Philadelphia: Saunders; 2005. pp. 261–301.

18.

Dierdorf SF, Walton S. Anesthesia for patients with rare and coexisting diseas. In: Barash PG, Cullen BF, Stoelting RK, editors. Clinic anesthesia, 5th edn. Philadelphia: Lippincott; 2006. pp. 502–28.

19.

Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–58.CrossRefPubMed

20.

Ozer N, Yorgun H, Canpolat U, Elibol B. Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. Anadolu Kardiyol Derg. 2014;14(2):121–7.CrossRefPubMed

21.

Rasmussen VG, Poulsen SH, Dupont E, Ostergaard K, Safikhany G, Egeblad H. Ergotamine-derived dopamine agonists and left ventricular function in Parkinson patients: systolic and diastolic function studied by conventional echocardiography, tissue Doppler imaging, and two-dimensional speckle tracking. Eur J Echocardiogr. 2008;9(6):803–8.CrossRefPubMed

22.

Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–44.CrossRefPubMed

23.

Jankovic J, Stacy M. Medical management of levodopaassociated motor complications in patients with Parkinson’s disease. CNS Drugs. 2007;21(8):677–92.CrossRefPubMed

24.

Mosnaim AD, Abiola R, Wolf ME, Perlmuter LC. Etiology and risk factors for developing orthostatic hypotension. Am J Ther. 2010;17(1):86–91.CrossRefPubMed

25.

Jamnadas-Khoda J, Koshy S, Mathias CJ, et al. Are current recommendations to diagnose orthostatic hypotension in Parkinson’s disease satisfactory? Mov Disord. 2009;24(12):1747–51.CrossRefPubMed

26.

Wolf JP, Bouhaddi M, Louisy F, et al. Side-effects of L dopa on venous tone in Parkinson’s disease: a leg-weighing assessment. Clin Sci. 2006;110(3):369–77.CrossRefPubMed

27.

Oka H, Yoshioka M, Onouchi K, et al. Characteristics of orthostatic hypotension in Parkinson’s disease. Brain. 2007;130(9):2425–32.CrossRefPubMed

28.

Poulsen SH, Andersen NH, Ivarsen PI, Mogensen CE, Egeblad H. Doppler tissue imaging reveals systolic dysfunction in patients with hypertension and apparent “isolated” diastolic dysfunction. J Am Soc Echocardiogr. 2003;16(7):724–31.CrossRefPubMed

29.

Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol. 2000;15(4):264–72.CrossRefPubMed

30.

Rajfer SI, Rossen JD, Nemanich JW, Douglas FL, Davis F, Osinski J. Sustained hemodynamic improvement during long-term therapy with levodopa in heart failure: role of plasma catecholamines. J Am Coll Cardiol. 1987;10(6):1286–93.CrossRefPubMed

31.

Kuznetsova T, Thijs L, Knez J, Herbots L, Zhang Z, Staessen JA. Prognostic value of left ventricular diastolic dysfunction in a general population. J Am Heart Assoc. 2014;3(3:e000789.CrossRefPubMedPubMedCentral

32.

Satpathy R, Mishra TK, Satpathy R, Satpathy HK, Barone E. Diagnosis and management of diastolic dysfunction and heart failure. Am Fam Physician. 2006;73(5):841–6.PubMed

33.

D’Andrea A, Stisi S, Bellissimo S, et al. Early impairment of myocardial function in systemic sclerosis: noninvasive assessment by Doppler myocardial and strain rate imaging. Eur J Echocardiogr. 2005;6(6):407–18.CrossRefPubMed

Titel: Effects of levodopa therapy on global left ventricular systolic function in patients with Parkinson disease
verfasst von: Zeki Yüksel Günaydın, M.D.
Osman Bektaş
Ahmet Karagöz
Fahriye Feriha Özer
Publikationsdatum: 01.07.2016
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 13-14/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-016-1026-5

Springer Medizin Österreich

Summary

Objectives

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13-14/2016

Incremental value of global longitudinal strain in prediction of all-cause mortality in predialysis and dialysis chronic kidney disease patients

Loeffler endocarditis: silent right ventricular myocardium!

MUW researcher of the month

Transcatheter aortic valve implantation in a cancer patient denied for surgical aortic valve replacement—a case report

Horizontal ECG in acute anterolateral myocardial infarction

Veranstaltungen